DDN
DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice[1].
Product Specifications
CAS Number
118006-14-7
UNSPSC
12352005
Hazard Statement
H301-H400
Target
Akt; ERK; Insulin Receptor
Related Pathways
MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Metabolic Disease
Smiles
O=C1C(Cl)=C(Cl)C(C2=C1C(OC(C)=O)=CC=C2OC(C)=O)=O
Molecular Formula
C14H8Cl2O6
Molecular Weight
343.12
Precautions
P264-P270-P273-P330-P391-P405-P501
References & Citations
[1]Kunyan He, et al. Identification of a molecular activator for insulin receptor with potent anti-diabetic effects. J Biol Chem. 2011 Oct 28;286 (43) :37379-88.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
252262 50 µL
SULT1A3 (Sulfotransferase Family, Cytosolic, 1A, phenol-preferring, Member 3, HAST, HAST3, M-PST, MGC117469, ST1A5, STM, SULT1A4, TL-PST)
Sign In for Pricing
View Details 
